Article Text

Download PDFPDF
Extended report
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension
  1. Jerome Avouac1,2,
  2. Irena Konstantinova3,
  3. Christophe Guignabert4,5,
  4. Sonia Pezet1,
  5. Jeremy Sadoine6,
  6. Thomas Guilbert1,
  7. Anne Cauvet1,
  8. Ly Tu4,5,
  9. Jean-Michel Luccarini3,
  10. Jean-Louis Junien3,
  11. Pierre Broqua3,
  12. Yannick Allanore1,2,6
  1. 1Université Paris Descartes, Sorbonne Paris Cité, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France
  2. 2Université Paris Descartes, Sorbonne Paris Cité , Service de Rhumatologie A, Hôpital Cochin, Paris, France
  3. 3Inventiva, Daix, France
  4. 4INSERM UMR_S 999, Le Plessis-Robinson, France
  5. 5Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
  6. 6EA 2496 Pathologie, Imagerieet Biothérapies Orofaciales, UFR Odontologie, Université ParisDescartes and PIDV, PRES Sorbonne Paris Cité, Montrouge, France
  1. Correspondence to Dr Jerome Avouac, Service de Rhumatologie A, Hôpital Cochin, Université Paris Descartes, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France; javouac{at}me.com

Footnotes

  • Handling editor Tore K Kvien

  • Contributors Study design: JA and YA. Conduction of experiments: JA, CG, SP, JS, TG, AC and LT. Data analysis: JA, CG, SP, JS, TG, AC, LT and YA. Writing/drafting and revising the manuscript: JA, IK, CG, SP, JS, TG, AC, LT, J-ML, J-LJ, PB and YA. Final approval of the manuscript: JA, IK, CG, SP, JS, TG, AC, LT, J-ML, J-LJ, PB and YA.

  • Funding Fundings were supplied by INSERM, ATIP/AVENIR programme and Inventiva. Inventiva was not involved in the study design and data acquisition.

  • Competing interests JA has/had consultancy relationship and/or has received research funding in relationship with the treatment of systemic sclerosis from Actelion, Roche, Pfizer and Bristol-Myers Squibb. YA has/had consultancy relationship and/or has received research funding in relationship with the treatment of systemic sclerosis from Actelion, Bayer, Biogen Idec, Bristol-Myers Squibb, Genentech/Roche, Inventiva, Medac, Pfizer, Sanofi/Genzyme, Servier and UCB. IK, J-ML and PB are employed by Inventiva. J-LJ has consultancy relationship with Inventiva.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Handling editor Tore K Kvien

  • Contributors Study design: JA and YA. Conduction of experiments: JA, CG, SP, JS, TG, AC and LT. Data analysis: JA, CG, SP, JS, TG, AC, LT and YA. Writing/drafting and revising the manuscript: JA, IK, CG, SP, JS, TG, AC, LT, J-ML, J-LJ, PB and YA. Final approval of the manuscript: JA, IK, CG, SP, JS, TG, AC, LT, J-ML, J-LJ, PB and YA.

  • Funding Fundings were supplied by INSERM, ATIP/AVENIR programme and Inventiva. Inventiva was not involved in the study design and data acquisition.

  • Competing interests JA has/had consultancy relationship and/or has received research funding in relationship with the treatment of systemic sclerosis from Actelion, Roche, Pfizer and Bristol-Myers Squibb. YA has/had consultancy relationship and/or has received research funding in relationship with the treatment of systemic sclerosis from Actelion, Bayer, Biogen Idec, Bristol-Myers Squibb, Genentech/Roche, Inventiva, Medac, Pfizer, Sanofi/Genzyme, Servier and UCB. IK, J-ML and PB are employed by Inventiva. J-LJ has consultancy relationship with Inventiva.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.